RetinalGenix Technologies (RTGN) Amortization of Deferred Charges (2025 - 2026)
RetinalGenix Technologies (RTGN) reported Amortization of Deferred Charges of $642.0 for Q1 2026, little changed on a YoY basis from $641.0 in Q1 2025, and little changed sequentially from $641.0 in Q1 2025.
RetinalGenix Technologies (RTGN) Amortization of Deferred Charges (2025 - 2026) Analysis & Trends
RetinalGenix Technologies (RTGN) has 2 years of Amortization of Deferred Charges data on file, last reported at $642.0 in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.03 Bn | 6.27 Bn |
| 2 | Stryker | 128.82 Bn | 125.95 Bn | 3.81 Bn |
| 3 | Medtronic | 108.46 Bn | 99.24 Bn | 6.41 Bn |
| 4 | Boston Scientific | 68.25 Bn | 66.79 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 47.64 Bn | 43.97 Bn | 1.29 Bn |
| 6 | Dexcom | 28.55 Bn | 27.43 Bn | 750.30 Mn |
| 7 | GE HealthCare Technologies | 28.51 Bn | 26.22 Bn | 1.98 Bn |
| 8 | Smith & Nephew | 26.96 Bn | 26.39 Bn | - |
| 9 | Koninklijke Philips | 25.42 Bn | 22.29 Bn | 2.07 Bn |
| 10 | RetinalGenix Technologies | 75.02 Mn | 75.02 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 642.00 |
| Mar 31, 2026 | 642.00 |
| Mar 31, 2025 | 641.00 |
| Mar 31, 2025 | 641.00 |